Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice

Cell Cycle

Volumn 10, Issue 24, 2011, Pages 4230-4236

  Anisimov, Vladimir N ^a   Zabezhinski, Mark A ^a   Popovich, Irina G ^a   Piskunova, Tatiana S ^a   Semenchenko, Anna V ^a   Tyndyk, Margarita L ^a   Yurova, Maria N ^a   Rosenfeld, Svetlana V ^a   Blagosklonny, Mikhail V ^b  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Aging; Gerosuppressants; Longevity; mTOR; Rapamycin

Indexed keywords

RAPAMYCIN;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; ESTRUS CYCLE; FEMALE; FLUID INTAKE; FOOD INTAKE; INBRED STRAIN; LIFESPAN; LONGEVITY; MOUSE; NONHUMAN; WEIGHT GAIN;

EID: 83755165458     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.24.18486     Document Type: Article

References (51)

1. Blagosklonny MV, Campisi J, Sinclair DA. Aging: past, present and future. Aging 2009; 1:1-5; PMID:20157590.
2. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogenous mice. Nature 2009; 460:392-5; PMID:19587680.
3. Blagosklonny MV. Rapamycin and quasi-programmed aging: Four years later. Cell Cycle 2010; 9:1859-62; PMID:20436272; http://dx.doi.org/10.4161/cc.9.10. 11872.
4. Kaeberlein M, Powers RW, 3rd, Steffen KK, Westman EA, Hu D, Dang N, et al. Regulation of yeast replicative lifespan by TOR and Sch9 in response to nutrients. Science 2005; 310:1193-6; PMID:16293764; http://dx.doi.org/10.1126/ science.1115535.
5. Powers RW, 3rd, Kaeberlein M, Caldwell SD, Kennedy BK, Fields S. Extension of chronological lifespan in yeast by decreased TOR pathway signaling. Genes Dev 2006; 20:174-84; PMID:16418483; http://dx.doi.org/10.1101/gad. 1381406.
6. Pan Y, Shadel GS. Extension of chronological lifespan by reduced TOR signaling requires downregulation of Sch9p and involves increased mitochondrial OXPHOS complex density. Aging 2009; 1:131-45; PMID:20157595.
7. Heeren G, Rinnerthaler M, Laun P, von Seyerl P, Kossler S, Klinger H, et al. The mitochondrial ribosomal protein of the large subunit, Afo1p, determines cellular longevity through mitochondrial back-signaling via TOR1. Aging 2009; 1:622-36; PMID:20157544.
8. Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 2008; 7:3355-61; PMID:18948731; http://dx.doi.org/10.4161/cc.7.21.6919.
9. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle 2009; 8:1888-95; PMID:19471117; http://dx.doi.org/10.4161/cc.8.12.8606.
10. Demidenko ZN, Blagosklonny MV. Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential. Aging 2009; 1:1008-16; PMID:20157583.
11. Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle 2009; 8:1896-900; PMID:19478560; http://dx.doi.org/10. 4161/cc.8.12.8809.
12. Pospelova TV, Demidenko ZN, Bukreeva EI, Pospelov VA, Gudkov AV, Blagosklonny MV. Pseudo-DNA damage response in senescent cells. Cell Cycle 2009; 8:4112-8; PMID:19946210; http://dx.doi.org/10.4161/cc.8.24.10215.
13. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci USA 2010; 107:9660-4; PMID:20457898; http://dx.doi.org/10.1073/pnas.1002298107.
14. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging 2010; 2:344-52; PMID:20606252.
15. Leontieva OV, Gudkov AV, Blagosklonny MV. Weak p53 permits senescence during cell cycle arrest. Cell Cycle 2010; 9:4323-7; PMID:21051933; http://dx.doi.org/10.4161/cc.9.21.13584.
16. Leontieva OV, Blagosklonny MV. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging 2010; 2:924-35; PMID:21212465.
17. Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, Muller F. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 2003; 426:620; PMID:14668850; http://dx.doi.org/10.1038/426620a.
18. Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol 2004; 14:885-90; PMID:15186745; http://dx.doi.org/10.1016/j.cub.2004.03. 059.
19. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian lifespan. Science 2009; 326:140-4; PMID:19797661; http://dx.doi.org/10.1126/science.1177221.
20. Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL, et al. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab 2010; 11:453-65; PMID:20519118; http://dx.doi.org/10.1016/j. cmet.2010.05.001.
21. Moskalev AA, Shaposhnikov MV. Pharmacological Inhibition of Phosphoinositide 3 and TOR Kinases Improves Survival of Drosophila melanogaster. Rejuvenation Res 2010; 13:246-7; PMID:20017609; http://dx.doi.org/10.1089/rej. 2009.0903.
22. Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, et al. Mechanisms of lifespan extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 2010; 11:35-46; PMID:20074526; http://dx.doi.org/10. 1016/j.cmet.2009.11.010.
23. Fontana L, Partridge L, Longo VD. Extending healthy lifespan - from yeast to humans. Science 2010; 328:321-6; PMID:20395504; http://dx.doi.org/10.1126/ science.1172539.
24. Bjedov I, Partridge L. A longer and healthier life with TOR downregulation: genetics and drugs. Biochem Soc Trans 2011; 39:460-5; PMID:21428920; http://dx.doi.org/10.1042/BST0390460.
25. Partridge L, Alic N, Bjedov I, Piper MD. Ageing in Drosophila: the role of the insulin/Igf and TOR signalling network. Exp Gerontol 2011; 46:376-81; PMID:20849947; http://dx.doi.org/10.1016/j.exger.2010.09.003.
26. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-84; PMID:16469695; http://dx.doi.org/10.1016/j. cell.2006.01.016.
27. Blagosklonny MV, Hall MN. Growth and aging: a common molecular mechanism. Aging 2009; 1:357-62; PMID:20157523.
28. Hands SL, Proud CG, Wyttenbach A. mTOR's role in ageing: protein synthesis or autophagy? Aging 2009; 1:586-97; PMID:20157541.
29. Cao K, Graziotto JJ, Blair CD, Mazzulli JR, Erdos MR, Krainc D, et al. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in hutchinson-gilford progeria syndrome cells. Sci Transl Med 2011; 3:89; PMID:21715679; http://dx.doi.org/10.1126/scitranslmed.3002346.
30. Blagosklonny MV. Validation of anti-aging drugs by treating age-related diseases. Aging 2009; 1:281-8; PMID:20157517.
31. Bové J, Martinez-Vicente M, Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci 2011; 12:437-52; PMID:21772323; http://dx.doi.org/10.1038/nrn3068.
32. Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2011.
33. Zhao C, Vollrath D. mTOR pathway activation in age-related retinal disease. Aging 2011; 3:346-7; PMID:21483039.
34. Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 2006; 5:2087-102; PMID:17012837; http://dx.doi.org/10.4161/cc.5.18.3288.
35. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, et al. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol 2010; 176:2092-7; PMID:20363920; http://dx.doi.org/10.2353/ajpath.2010. 091050.
36. Ikeno Y, Bronson RT, Hubbard GB, Lee S, Bartke A. Delayed occurrence of fatal neoplastic diseases in ames dwarf mice: correlation to extended longevity. J Gerontol A Biol Sci Med Sci 2003; 58:291-6; PMID:12663691; http://dx.doi.org/10.1093/gerona/58.4.B291.
37. Ikeno Y, Hubbard GB, Lee S, Cortez LA, Lew CM, Webb CR, et al. Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci 2009; 64:522-9; PMID:19228785; http://dx.doi.org/10.1093/gerona/glp017.
38. Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther 2008; 7:1520-4; PMID:18769112; http://dx.doi.org/10.4161/cbt.7.10.6663.
39. Anisimov VN. Metformin for aging and cancer prevention. Aging 2010; 2:760-74; PMID:21084729.
40. Longo VD, Fontana L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol Sci 2010; 31:89-98; PMID:20097433; http://dx.doi.org/10.1016/j.tips.2009.11.004.
41. Blagosklonny MV. Calorie restriction: Decelerating mTOR-driven aging from cells to organisms (including humans). Cell Cycle 2010; 9:683-8; PMID:20139716; http://dx.doi.org/10.4161/cc.9.4.10766.
42. Mostoslavsky R, Esteller M, Vaquero A. At the crossroad of lifespan, calorie restriction, chromatin and disease: meeting on sirtuins. Cell Cycle 2010; 9:1907-12; PMID:20458180; http://dx.doi.org/10.4161/cc.9.10.11481.
43. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, et al. Metformin slows down aging and extends lifespan of female SHR mice. Cell Cycle 2008; 7:2769-73; PMID:18728386; http://dx.doi.org/10.4161/ cc.7.17.6625.
44. Anisimov VN, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Egormin PA, et al. Gender differences in metformin effect on aging, lifespan and spontaneous tumorigenesis in 129/Sv mice. Aging 2010; 2:945-58; PMID:21164223.
45. Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Piskunova TS, et al. If started early in life, metformin treatment increases lifespan and postpones tumors in female SHR mice. Aging 2011; 3:148-57; PMID:21386129.
46. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, et al. Metformin extends lifespan of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010; 9:188-97; PMID:20016287; http://dx.doi.org/10.4161/cc.9.1. 10407.
47. Anisimov VN, Egormin PA, Bershtein LM, Zabezhinskii MA, Piskunova TS, Popovich IG, et al. Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med 2005; 139:721-3; PMID:16224592; http://dx.doi.org/10.1007/s10517-005-0389-9.
48. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, et al. Effect of metformin on lifespan and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005; 40:685-93; PMID:16125352; http://dx.doi.org/10.1016/j.exger.2005.07.007.
49. Blagosklonny MV. Metformin and sex: Why suppression of aging may be harmful to young male mice. Aging 2010; 2:897-9; PMID:21212463.
50. Anisimov VN, Khavinson VK, Provinciali M, Alimova IN, Baturin DA, Popovich IG, et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer 2002; 101:7-10; PMID:12209581; http://dx.doi.org/10.1002/ijc.10570.
51. Rosenfeld SV, Togo EF, Mikheev VS, Popovich IG, Khavinson V, Anisimov VN. Effect of epithalon on the incidence of chromosome aberrations in senescence-accelerated mice. Bull Exp Biol Med 2002; 133:274-6; PMID:12360351; http://dx.doi.org/10.1023/A:1015899003974.